

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

(37 CFR 1.98(b))

ATTY. DOCKET NO.
USB 98 AX CNR NFK

BERNARD 856796

APPLICANT
François HIRSCH

FILING DATE
May 25, 2001

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
BF	AD	WO 99/06040	02/99	International			N/A
	AE						

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

BF	AF	M.DIGICAYLI OGLU et al., NEUROPROTECTION FROM NITRIC OXIDE BY ERYTHROPOIETIN (EPO) IS MEDIATED BY NFKappaB, Society for Neuroscience, Part 2, Los Angeles, CA, November 7012, 1998
	AG	A.HAEFFNER et al., INHIBITORY EFFECT OF GROWTH HORMONE ON TNF-alpha SECRETION AND NUCLEAR FACTOR -kappaB TRANSPORTATION IN LIPOPOLYSACCHARIDE-STIMULATED HUMAN MONOCYTES, Journal of Immunology, Feb. 1, 1997, Vol. 3, No. 1, pp 1310-1314
	AH	C.Y.WANG et al., TNF- AND CANCER THERAPY-INDUCED APOPTOSIS: POTENTIATION BY INHIBITION OF NF-kappaB, Science, Vol. 274, No. 5288, Nov. 1, 1996, pp 784-787
BF	AI	A.HAEFFNER et al., GROWTH HORMONE PREVENTS HUMAN MONOCYTE CELL FROM FAS-MEDIATED APOPTOSIS BY UP-REGULATING Bcl-2 EXPRESSION, European Journal of Immunology, Vol. 29, No. 1, Jan. 1999, pp 334-44
	AJ	
	AK	
	AL	

EXAMINER

Bowles-Feltard

DATE CONSIDERED

2/19/05

EXAMINER: Initial citation consider d. Draw line through citation if not in confr manc and n t considered.
Include copy of this form with next communication to applicant.